Coeptis Therapeutics (NASDAQ:ZSQR) Trading 14% Higher – What’s Next?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR – Get Free Report) rose 14% during mid-day trading on Monday . The company traded as high as $10.68 and last traded at $10.61. Approximately 168,595 shares changed hands during mid-day trading, an increase of 88% from the average daily volume of 89,587 shares. The stock had previously closed at $9.31.

Coeptis Therapeutics Price Performance

The firm has a market capitalization of $542.08 million, a P/E ratio of -4.18 and a beta of -0.09. The business has a fifty day moving average of $11.97 and a 200-day moving average of $13.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25.

Get Coeptis Therapeutics alerts:

Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The business had revenue of $0.11 million during the quarter.

Hedge Funds Weigh In On Coeptis Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC grew its holdings in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares in the last quarter. Yorkville Advisors Global LP bought a new position in Coeptis Therapeutics during the 3rd quarter valued at $140,000. Marshall Wace LLP bought a new position in Coeptis Therapeutics during the 4th quarter valued at $259,000. State Street Corp boosted its stake in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after purchasing an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares in the last quarter. 13.88% of the stock is owned by institutional investors.

Coeptis Therapeutics Company Profile

(Get Free Report)

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

See Also

• Five stocks we like better than Coeptis Therapeutics
• Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
• Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
• Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
• Was Hormel’s Q2 Earnings Report the Turnaround Investors Needed?

Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.